To contact us or to ask for an appointment please call: +49-251-788-788-0, send us an email to info (at) ghi-muenster.de. Emergency appointments can be accomodated. We look forward to hearing from you!
First information about Huntington's disease in German is available in a booklet entitled "Huntington's disease compact" providing treatment options and frequently asekd questions for patients and caregivers in lay language. It was publihed by Thieme in 2022 and edited by Drs. Ralf Reilmann and Bernhard Landwehrmeyer.
The booklet is available online at no charge if you click on the picture on the right:
"SELECT-HD" aims to selectively reduce production of the mutated huntingtin using an ASO.Read more
The "PIVOT-HD" study sponsored by PTC Therapeutics investigates an oral drug aiming to lower the production of the protein huntingtin.Read more
GHI participates in a study sponsorded by SOM-Biotech that investigates a new drug aiming to redcue chora in Huntington's disease.Read more
Die Firma Roche hat in einer Pressemeldung mitgeteilt, dass die Generation-HD1 Studie mit dem Antise...Read more
GHI will shortly start the pivotal phase III trial PROOF-HD with Pridopidine. Several studies observ...Read more
Huntington patients and pre-symptomatic gene carriers now have the possibility to participate in the SHIELD-HD study at GHI.Read more
We're a multidisciplinary team of neurologists, physicians, study nurses and natural scientists, to provide clinical care and advance clinical research in HD.Read more
Contact us if you are interested in clinical studies that are currently conducted. GHI participates in most of the clinical trials that are conducted in HD globally.Read more